Annovis Bio Inc. (NYSE: ANVS) has provided third-quarter 2026 corporate updates, highlighting progress in its pivotal Phase 3 DUET-AD trial of buntanetap for early Alzheimer's disease and preparations for a planned New Drug Application. The fully enrolled trial includes 862 patients and features two prespecified efficacy readouts at six and 18 months to evaluate symptomatic and disease-modifying effects, respectively. Topline results from the six-month treatment period are expected in March 2027, and the company plans to begin transitioning eligible patients into its Alzheimer's open-label extension study by the end of November 2026.
The timeline is significant for patients and investors because it sets a concrete near-term catalyst in the high-risk, high-reward field of neurodegenerative disease research. Alzheimer's affects millions worldwide, and a disease-modifying oral therapy would represent a major advance. Annovis also reported enrollment of 326 patients in its Parkinson's disease open-label extension study, designed to evaluate the long-term safety and efficacy of buntanetap over 36 months. Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action.
In September, Annovis partnered with Weave Bio to support regulatory documentation and preparation of its planned NDA. The company subsequently closed an approximately $21 million underwritten public offering on Nov. 6, 2026, including a $5 million investment from its board chairman. Management said the financing is expected to support operations through the anticipated March 2027 topline data readout. That funding runway reduces immediate dilution risk and signals insider confidence, though the offering also dilutes existing shareholders.
For industry observers, the March 2027 readout will be a key test of the RNA-targeting approach and could influence investment in similar multi-target therapies. If successful, Annovis would be positioned to file an NDA, potentially bringing a new oral treatment option to the Alzheimer's market. For more details, the full press release is available at https://ibn.fm/6c61g, and the company's website is www.annovisbio.com. Investors can also follow the company on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
The announcement was distributed through BioMedWire, a communications platform focused on biotechnology and life sciences, which is part of the Dynamic Brand Portfolio at IBN. BioMedWire provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. The company's full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
